Addex Therapeutics
Discovers and develops small molecule oral drugs to treat a range of medical conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $2.1m | Post IPO Equity |
| Total Funding | 000k | ||
| CHF | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 31 % | (19 %) | (51 %) | 13 % | (75 %) | 271 % | (50 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (327 %) | (520 %) | (1418 %) | (614 %) | (1154 %) | (222 %) | (381 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (356 %) | (526 %) | (1463 %) | (654 %) | 1746 % | (363 %) | (660 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 287 % | 440 % | 1031 % | 170 % | 108 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Addex Therapeutics is a clinical-stage pharmaceutical company that specializes in developing and commercializing a new class of oral drugs called allosteric modulators. These drugs are designed to treat neurological disorders, which are diseases that affect the brain and nervous system. The company focuses on creating small molecule drugs, which are simpler and easier to produce compared to larger, more complex drugs.
Addex Therapeutics operates in the pharmaceutical and biotechnology market, targeting conditions such as epilepsy, Parkinson's disease, dystonia (a movement disorder), addiction, PTSD (post-traumatic stress disorder), and various neurodegenerative disorders. The company serves a range of clients, including healthcare providers, hospitals, and research institutions that are involved in treating and studying neurological conditions.
The business model of Addex Therapeutics revolves around research and development (R&D) of these innovative drugs. They conduct clinical trials to test the safety and effectiveness of their drugs before they can be approved for use by regulatory bodies like the FDA (Food and Drug Administration). Once approved, these drugs can be marketed and sold to healthcare providers and patients.
Addex makes money primarily through the commercialization of its drugs. This includes selling the drugs directly, licensing their technology to other pharmaceutical companies, and forming partnerships for co-development and distribution. They also receive funding from investors and grants to support their R&D activities.
In summary, Addex Therapeutics is a forward-thinking pharmaceutical company dedicated to creating new treatments for neurological disorders using allosteric modulators. Their focus on innovative drug development and strategic partnerships positions them as a key player in the biotech industry.
Keywords: allosteric modulators, neurological disorders, clinical-stage, pharmaceutical, epilepsy, Parkinson's disease, addiction, PTSD, drug development, biotechnology.
